JOP20220187A1 - لقاح فيروس الورم الحليمي البشري (hpv) - Google Patents

لقاح فيروس الورم الحليمي البشري (hpv)

Info

Publication number
JOP20220187A1
JOP20220187A1 JOP/2022/0187A JOP20220187A JOP20220187A1 JO P20220187 A1 JOP20220187 A1 JO P20220187A1 JO P20220187 A JOP20220187 A JO P20220187A JO P20220187 A1 JOP20220187 A1 JO P20220187A1
Authority
JO
Jordan
Prior art keywords
hpv
hpv vaccine
human papillomavirus
vlps
antibody
Prior art date
Application number
JOP/2022/0187A
Other languages
English (en)
Inventor
S Espeseth Amy
J Bett Andrew
Fu Tong-Ming
P Bilello John
E Gindy Marian
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of JOP20220187A1 publication Critical patent/JOP20220187A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

يوفر الكشف الحالي، من بين أمور أخرى، تركيبة صيدلانية تتضمن مادة مساعدة دهنية نانوية الجسيمات ومضاد فيروس ورم حليمي بشري (HPV) يشتمل على جسيمات شبيهة بفيروس HPV (VLPs) لنوع واحد على الأقل من فيروس الورم الحليمي البشري (HPV) مختار من المجموعة التي تتكون من أنواع HPV: 6، 11، 16، 18، 26، 31، 33، 35، 39، 45، 51، 52، 53، 55، 56، 58، 59، 66، 68، 73، و82. الشكل 1أ
JOP/2022/0187A 2020-02-14 2022-08-14 لقاح فيروس الورم الحليمي البشري (hpv) JOP20220187A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976673P 2020-02-14 2020-02-14
PCT/US2021/017157 WO2021163002A1 (en) 2020-02-14 2021-02-09 Hpv vaccine

Publications (1)

Publication Number Publication Date
JOP20220187A1 true JOP20220187A1 (ar) 2023-01-30

Family

ID=74853762

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0187A JOP20220187A1 (ar) 2020-02-14 2022-08-14 لقاح فيروس الورم الحليمي البشري (hpv)

Country Status (21)

Country Link
US (3) US20230123584A1 (ar)
EP (1) EP4103227A1 (ar)
JP (1) JP2023516904A (ar)
KR (1) KR20220140901A (ar)
CN (1) CN115103687A (ar)
AR (1) AR121292A1 (ar)
AU (1) AU2021219652A1 (ar)
BR (1) BR112022015313A2 (ar)
CA (1) CA3166256A1 (ar)
CL (1) CL2022002167A1 (ar)
CO (1) CO2022011392A2 (ar)
CR (1) CR20220395A (ar)
DO (1) DOP2022000168A (ar)
EC (1) ECSP22063122A (ar)
IL (1) IL295234A (ar)
JO (1) JOP20220187A1 (ar)
MX (1) MX2022009964A (ar)
PE (1) PE20230493A1 (ar)
PH (1) PH12022552075A1 (ar)
TW (1) TW202140069A (ar)
WO (1) WO2021163002A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022015313A2 (pt) * 2020-02-14 2022-09-27 Merck Sharp & Dohme Llc Vacina de hpv
CA3229064A1 (en) * 2021-08-19 2023-02-23 Andrew Bett Thermostable lipid nanoparticle and methods of use thereof
CN115850686B (zh) * 2021-09-27 2026-01-30 广州谷森制药有限公司 新型氘代聚乙二醇脂质化合物
CA3255112A1 (en) * 2022-03-23 2023-09-28 Nanovation Therapeutics Inc. HIGH STEROL LIPID NANOPARTICLES

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
WO1998000110A1 (en) 1996-07-03 1998-01-08 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
AU2003301148A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
ES2381964T3 (es) 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
BRPI0509079B8 (pt) 2004-03-24 2021-07-06 Merck & Co Inc molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
WO2007086883A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2006114312A2 (en) 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101622008A (zh) * 2007-03-09 2010-01-06 默克公司 乳头瘤病毒疫苗组合物
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20100055168A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20100076055A1 (en) 2008-04-16 2010-03-25 Abbott Laboratories Cationic Lipids and Uses Thereof
US20100104629A1 (en) 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
WO2010030730A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
WO2010030739A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
BRPI1010692A2 (pt) 2009-06-17 2016-03-15 Sharp Kk "circuito de acionamento de exibição, dispositivo de exibição e método de acionamento de exibição"
WO2011022460A1 (en) 2009-08-20 2011-02-24 Merck Sharp & Dohme Corp. Novel cationic lipids with various head groups for oligonucleotide delivery
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
MX349088B (es) 2010-09-20 2017-07-10 Merck Sharp & Dohme Lípidos catiónicos novedosos de bajo peso molecular para la entrega de oligonucleótidos.
KR102049988B1 (ko) * 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
WO2015130584A2 (en) * 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
AU2016342376A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
BR112022015313A2 (pt) * 2020-02-14 2022-09-27 Merck Sharp & Dohme Llc Vacina de hpv

Also Published As

Publication number Publication date
WO2021163002A1 (en) 2021-08-19
IL295234A (en) 2022-10-01
US20210252138A1 (en) 2021-08-19
US20230123584A1 (en) 2023-04-20
CL2022002167A1 (es) 2023-02-03
AU2021219652A1 (en) 2022-08-18
MX2022009964A (es) 2022-09-19
TW202140069A (zh) 2021-11-01
AR121292A1 (es) 2022-05-04
DOP2022000168A (es) 2022-09-30
KR20220140901A (ko) 2022-10-18
US20230270850A1 (en) 2023-08-31
PH12022552075A1 (en) 2024-02-12
PE20230493A1 (es) 2023-03-23
ECSP22063122A (es) 2022-11-30
JP2023516904A (ja) 2023-04-21
CN115103687A (zh) 2022-09-23
CO2022011392A2 (es) 2022-08-19
US11638754B2 (en) 2023-05-02
CA3166256A1 (en) 2021-08-19
CR20220395A (es) 2022-10-27
EP4103227A1 (en) 2022-12-21
BR112022015313A2 (pt) 2022-09-27

Similar Documents

Publication Publication Date Title
WO2020163719A3 (en) Nanoparticle-based influenza virus vaccines and uses thereof
MX2022009964A (es) Vacuna contra hpv.
Li et al. Peptide vaccine: progress and challenges
Levast et al. Vaccine potentiation by combination adjuvants
JP2008534467A5 (ar)
EA201171033A1 (ru) Вакцины против гриппа со сниженным количеством сквалена
TW200722101A (en) Novel composition
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
CY1111552T1 (el) Χρηση hpv16 και hpv18 ως εμβολιο εναντι ενος ή περισσοτερων ογκογονικου hpv τυπου 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
SG165378A1 (en) Functional influenza virus-like particles (vlps)
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
DE60332377D1 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
Vassilieva et al. Skin immunization by microneedle patch overcomes statin-induced suppression of immune responses to influenza vaccine
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
Francis et al. Solid lipid nanoparticles delivering a DNA vaccine encoding Helicobacter pylori Urease A Subunit: Immune analyses before and after a mouse model of infection
ZA202201571B (en) Polyvalent immunogenicity composition for human papillomavirus
MA40181A (fr) Système de rhinovaccination pour vaccin contre la grippe
MX2024002144A (es) Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
EP1425423A4 (en) TRANSCUTANEOUS IMMUNIZATION AGAINST PAPILLOMA VIRUSES WITH VIRUSUAL PAPILLOMA VIRUS PARTICLES
EP1790332A4 (en) VACCINE FOR ORAL ADMINISTRATION
Wang et al. Immunoengineered adjuvants for universal vaccines against respiratory viruses
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
SG153837A1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
Geeraedts et al. Influenza vaccines: what do we want and how can we get it?